Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).
Among those enrolled in the trial, the overall response rate (ORR) was 96% with a complete response (CR) rate of 72%. For the 18 patients within the follicular lymphoma cohort of the trial, the ORR demonstrated was 94% with 14 patients (78%) showing a CR as their best response. Two patients with diffuse large B-cell lymphoma were treated, 1 with a prior CD19 CAR T treatment, and 1 who had achieved complete remission. Further, 2 patients with Waldenstrom macroglobulinemia responded with 1 having a complete remission, and the other in a very good partial remission.
Findings revealed there to be a favorable safety profile demonstrated along with no reports of grade 3/4 cytokine release syndrome. Additionally, no grade 3/4 neurotoxicity was observedin the overall patient population.
0:08 | We continue to see very high efficacy with this CAR T product. As I mentioned, 25 patients that have been treated so far and reached their disease assessment time point at the time of our presentation [at TCT]. Among follicular lymphoma patients, we are currently observing an overall response rate of 94% with complete response rate of 78% as the best response which of course, shows a very high efficacy profile for this product. Overall the study shows 96% overall response and 72% complete response.
0:48 | Out of the diffuse large B-cell lymphoma patients, we have treated 2 patients, 1 with a prior CD19 CAR treatment and 1 patient achieved a complete remission. The other patient had a partial response, and a repeat PET scan will happen soon. The CLL patient achieved a complete remission and the Waldenstrom patients both responded. One converted from a very good partial response to complete remission, and the other is currently in a very good partial remission. So very high efficacy, and these remissions are ongoing.
1:21 | We have a patient with more than 2 years of follow up after CR and we have 5 patients who are in CR, more than 1 year. These remissions are ongoing, and that is consistent with the CAR T-cell persistence that we are observing these patients. Another important feature that we have observed is the safety profile of this CAR T. This is an outpatient CAR T, so we don't have any planned admission for this study. Only the first patients of these cohorts spent 1 night in the hospital for observation. But otherwise, all treatments are given in the outpatient setting.
2:13 | We have not observed any grade 3 or 4 cytokine release syndrome in the entire cohort, and also no grade 3 or 4 ICANS or neurotoxicity. All of the CRS and ICANS were grade 1 or 2. We actually only had 2 patients with ICANS, 1 with grade 1 and 1 with grade 2. Among follicular lymphoma patients, we have not observed any neurotoxicity of any grades.